健康はキョーリンの願いです。

First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2027

July 30, 2026

KYORIN Pharmaceutical Co., Ltd.

■ Disclaimer

This material contains performance forecasts, goals and plans, and other forward-looking statements related to the Group.
These statements are based on the judgment of the Group′s assumptions and outlooks based on the information and forecasts available at the time of preparation of this material, and contain known or unknown risks and uncertainties. Therefore, due to various factors that may occur, the actual performance, progress / success / failure of the development and other insights may differ significantly from the description. It also contains information about medicines (including those under development), but the description is not for the purpose of advertising or medical advice.

Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Overview of Financial Results for FY2026 1Q

(JPY millions)	FY2023 1Q (Apr-Jun)	FY2024 1Q (Apr-Jun)	FY2025 1Q (Apr-Jun)	**FY2026 1Q (Apr-Jun)**	**Change (%)**	Interim term FY2026 (Forecast)	Change (%)	Full term FY2026 (Forecast)	Change (%)
Net sales	27,854	28,419	30,229	**29,654**	**−1.9**	57,800	−1.6	121,800	−3.5
Operating profit	871	1,150	2,368	**964**	**−59.3**	−300	−	2,000	−43.9
Ordinary profit	1,074	1,417	2,624	**1,241**	**−52.7**	−100	−	2,300	−42.9
Profit attributable to owners of parent	787	885	2,100	**824**	**−60.8**	0	−100.0	1,500	−56.5

First Quarter Consolidated Financial Results

[Net sales] Net sales decreased by 575 million yen year-on-year to 29,654 million yen. Sales of new drugs (Japan) fell below the same period of the previous year, although the mainstay product "Beova" grew, sales were affected by the NHI drug price revisions. Sales of new drugs (overseas) decreased due to a reaction to gatifloxacin-related revenue recorded in the previous period. Sales of generic drugs increased, driven by contributions from authorized generics (AGs) and newly listed generic drugs launched in FY2026.

[Profit] Gross profit decreased by 1,083 million yen year-on-year due to the decline in net sales. SG&A expenses increased by 321 million yen (R&D expenses increased by 390 million yen) . As a result, operating profit came to 964 million yen, down 1,404 million yen or 59.3%, year-on-year. Ordinary profit was 1,241 million yen (down 52.7%, year-on-year). Profit attributable to owners of parent was 824 million yen (down 60.8%, year-on-year)

Consolidated Financial Results for FY2026 (Forecast)

The forecast for the interim term and full term announced on May 12, 2026 remain unchanged at this moment.
(Progress compared with the forecast for the interim term, net sales: 51.3%, operating profit: - %)
There is no change to the dividend plan announced on May 12, 2026 (Annual dividend of 25 yen per share).

*Beginning of FY2024, the company changed accounting policies. The results for FY2023 are presented after retroactive adjustment.

Highlights of Business Performance



(JPY billions)

Net sales decreased (−0.5)

- Decrease in sales of new drugs (Japan)
  - Beova sales grew
  - Impact of NHI drug price revision (Kyorin Pharmaceutical: 4% range), etc.
- Decrease in sales of new drugs (Oversea)
- Increase in sales of generic drugs

Cost of sales ratio increased (+2.8%point)

<Factors of decrease>

- Beova sales grew

<Factors of increase>

- Impact of NHI drug price revisions, etc.
- Rebound decline in gatifloxacin-related revenue

Gross profit decreased (−1.1)

SG&A cost increased (+0.3)

- R&D expenses increased (+0.4)
- SG&A (excluding R&D) decreased (-0.1)
  - Cost reduction
  - Increase in license fees

Operating profit decreased (−1.4)

Financial Results

(JPY billions)	FY2025 1Q	**FY2026 1Q**	Change
Net sales	30.2	**29.7**	−0.5
New drugs, etc. (Japan)	21.5	**21.1**	−0.4
New drugs (Overseas)	0.4	**0.1**	−0.3
Generic drugs	8.4	**8.5**	+0.1
Operating profit	2.4	**1.0**	−1.4
Ordinary profit	2.6	**1.2**	−1.4
Profit attributable to owners of parent	2.1	**0.8**	−1.3

(JPY billions) (Year on Year)

■Net sales 29.7 (−0.5)

●New drugs (Japan) 21.1 (−0.4)

	FY2025 (1Q)		FY2026 (1Q)	
・Beova	6.2	⇒	7.3	(+1.1)
・Lasvic	2.0	⇒	1.9	(−0.1)
・Flutiform	3.3	⇒	3.0	(−0.3)
・Lyfnua	0.2	⇒	0.2	(0)
・Mucodyne	1.0	⇒	0.9	(−0.1)
・Pentasa	3.2	⇒	2.7	(−0.5)
・Desalex	2.0	⇒	1.5	(−0.5)
・Kipres	0.5	⇒	0.3	(−0.2)

●New drugs (Overseas) 0.1 (−0.3)

Rebound decline in gatifloxacin-related revenue

●Generic drugs 8.5 (+0.1)

Contributions from AGs and new generic launches in FY2026

■Operating income 1.0 (−1.4)

●Cost of sales ratio : 58.9% (FY2025 1Q: 56.1%)

[Factors of decrease] Beova sales grew
[Factors of increase] NHI drug price revisions etc.
Rebound decline in gatifloxacin-related revenue

●R&D : 2.4 (FY2025 1Q: 2.0)

●SG&A (excluding R&D expenses) : 8.8 (FY2025 1Q: 8.9)

Cost reduction, increase in license fees

■Profit attributable to owners of parent 0.8 (−1.3)

Financial Result and Forecast

Kyorin

(JPY millions)	1Q (Apr-Jun)						Interim term		Full term	
	FY2025 (Actual)	**FY2026 (Actual)**	Change	Change (%)	Progress to interim term forecast (%)	Progress to full term forecast (%)	FY2025 (Actual)	FY2026 (Forecast)	FY2025 (Actual)	FY2026 (Forecast)
Net sales	30,229	**29,654**	−575	−1.9	51.3	24.3	58,731	57,800	126,257	121,800
New drugs, etc. (Japan)	21,492	**21,070**	−422	−2.0	51.8	25.2	41,405	40,700	87,113	83,500
New drugs (Overseas)	359	**131**	−227	−63.3	65.9	44.0	504	200	693	300
Generic drugs	8,377	**8,452**	+74	+0.9	50.6	22.3	16,822	16,700	38,451	37,900
Operating profit	2,368	**964**	−1,404	−59.3	−	48.2	1,363	−300	3,567	2,000
Ordinary profit	2,624	**1,241**	−1,382	−52.7	−	54.0	1,582	−100	4,031	2,300
Profit attributable to owners of parent	2,100	**824**	−1,276	−60.8	−	55.0	1,494	0	3,448	1,500

Main Product Sales Update

Kyorin

	(JPY billions)	1Q (Apr-Jun) FY2025 (Actual)	FY2026 (Actual)	Change	Change (%)	Progress to interim forecast (%)	Progress to full term forecast (%)	Interim term FY2025 (Actual)	FY2026 (Forecast)	Full term FY2025 (Actual)	FY2026 (Forecast)
New drugs, etc. (Japan)	**Beova (Kyorin)** (β3 adrenergic receptor agonist overactive bladder therapeutics)	6.2	**7.3**	+1.1	+17.5	56.8	27.4	12.3	12.9	25.8	26.7
	Lasvic (New quinolone synthetic antibacterial agent)	2.0	**1.9**	−0.1	−3.7	49.9	21.6	3.5	3.9	7.3	9.0
	Flutiform **(Combination drug for asthma treatment)**	3.3	**3.0**	−0.3	−7.9	51.6	24.7	6.3	5.9	12.8	12.3
	Lyfnua (selective P2X3 receptor antagonist for the treatment of chronic cough)	0.2	**0.2**	0	−9.8	41.9	21.0	0.5	0.5	0.9	1.0
	Mucodyne (Mucoregulant)	1.0	**0.9**	−0.1	−6.9	37.4	16.6	2.0	2.4	3.7	5.4
	Pentasa (Ulcerative colitis and Crohn's disease treatment)	3.2	**2.7**	−0.5	−14.6	53.2	26.6	6.3	5.1	12.3	10.2
	Desalex (Antiallergic Agent)	2.0	**1.5**	−0.5	−25.6	91.1	63.4	3.7	1.6	10.2	2.3
	Kipres (Leukotriene Receptor Antagonist)	0.5	**0.3**	−0.2	−42.6	76.0	30.4	0.9	0.4	2.2	1.0
	Milton (Disinfectant)	0.5	**0.4**	−0.1	−15.5	43.0	21.5	0.9	0.9	1.8	1.8
	Rubysta (Disinfectant)	0.2	**0.2**	0	−10.2	61.1	26.2	0.4	0.3	0.8	0.7
Generic drugs (AGs)	**Montelukast tablets "KM"** (Leukotriene Receptor Antagonist)	2.2	**2.5**	+0.3	+13.2	57.2	24.4	4.4	4.3	11.4	10.1
	Mometasone Nasal 50μg "KYORIN" (Spray type allergic rhinitis remedy)	0.6	**0.5**	−0.1	−18.0	46.3	11.9	1.1	1.0	4.5	3.9

Development pipeline
Main R&D Activities -1 (as of July 30, 2026)

Kyorin

Ph3 / Launch

※Updated

Code	Proposed Indication	Stage		Origin	Features	Note
		Japan	Overseas			
KRP-114VP	Overactive bladder	Ph3 (May 2026)	—	Merck	- β3-adrenergic receptor agonist - Enhances bladder relaxation during storage phase to increase capacity and improve OAB symptoms (urgency, frequency, and UUI)	Additional Indication for Beova in pediatric patients

※Following a comprehensive review of its development strategy, KYORIN has terminated the license agreement with aTyr for KRP-R120 and removed the program from its pipeline.

Digital Therapeutics (DTx)

Code	Proposed Indication	Stage	Partner	Features	Note
KRP-DT123	Tinnitus	Confirmatory Study (May 2026)	SUSUMED	- DTx for Tunnitus	Collaboration research and sales agreement for development of DTx in otolaryngology Field (Nov 2022)
KRP-DC125	Chronic Cough	Confirmatory Study (June 2026) ※	Hyfe	- DTx for Chronic Chough	Development and commercialization agreement for DTx for chronic cough (2024)

Development pipeline
Main R&D Activities-2 (as of July 30, 2026)

Kyorin

Ph1 ～ Ph2

Code	Proposed Indication	Stage		Origin	Features	Note
		Japan	Overseas			
KRP-S124	OSA etc.		Ph1 Bayer	Bayer	- ADRA2C antagonist - Centrally reduces upper airway collapse, with expected improvements in transient apnea and hypopnea	- License agreement for worldwide manufacturing, development, and commercialization rights (Dec 2024) - Scheduled to start Ph2 in FY2026
KRP-A225	Systemic Lupus Erythematosus (SLE), etc.		Ph1 Hinge Bio	Hinge Bio	- A bispecific antibody targeting CD19 and CD20 on the surface of B cells. - "Reset" the immune system through B cell depletion.	- Collaboration and License Agreement in Japan for SLE and other diseases (Sep 2025)
KRP-126	Neuropathic Pain		Ph1 BIODOL	BIODOL Therapeutics	- FLT3 Negative allosteric modulator - Exerts a negative modulatory effect on FLT3, a key driver of chronic pain onset and persistence, offering strong analgesic effects	- License agreement for development, manufacturing, and commercialization in Japan, South Korea, and Taiwan (Mar 2026) - Scheduled to start Ph1 (Japan) in FY2026

Licensing development (License-out)

Code	Proposed Indication	Stage	Licensee	Origin	Features	Note
KRP-M223	Allergic and inflammatory diseases involving mast cells, such CSU etc.	Pre-clinical	Novartis	In-house	MRGPRX2 antagonist	- License agreement to obtained the exclusive worldwide license to develop, manufacture, and commercialize KRP-M223 (Mar 2025) - Option rights for commercialization in Japan and manufacturing for the Japanese market

Other Major Agreements（as of July 30, 2026）

Kyorin

Other Agreements

※Updated

Product	Partner	Indication	Stage	Note
SIRTURO®	J&J	Multidrug-resistant pulmonary tuberculosis (MDR-TB)	Launched	- Exclusive distribution agreement in Japan (Mar 2026) - Initiated sole promotion (Jun 2026–; MDR-TB) - Plan to exclusively commercialize upon obtaining additional approval for pulmonary MAC disease
		Mycobacterium avium complex-lung disease (MAC-LD)	**Filed** (J&J) ※	
※Alesion® Eyelid Cream 0.5%	**Santen**	**Allergic conjunctivitis**	**Launched**	**- Joint marketing agreement in Japan (July 2026)** **- Plan to initiate promotion outside the field of ophthalmology (Aug 2026)**

※KYORIN has decided not to exercise its option rights for CYR-064 at this time and has removed the program from its pipeline.